Patents Assigned to Minerva Biotechnologies Corporation
-
Publication number: 20130190495Abstract: This invention generally relates to compositions and methods for cancer treatment and, in particular, to compositions able to interact (e.g., bind to) with MUC1 growth factor receptor or its ligands, and methods for treating the same. The invention also relates to assays or use of such compositions for the treatment of patients susceptible to or exhibiting symptoms characteristic of cancer or tumorigenesis. Other compositions of the present invention useful for the treatment or prevention of cancer or tumorigenesis include homologs, analogs, derivatives, enantiomers or functional equivalents. The present compositions can also be packaged in kits in some cases.Type: ApplicationFiled: December 7, 2012Publication date: July 25, 2013Applicant: MINERVA BIOTECHNOLOGIES CORPORATIONInventor: MINERVA BIOTECHNOLOGIES CORPORATION
-
Patent number: 8349853Abstract: This invention generally relates to compositions and methods for cancer treatment and, in particular, to compositions able to interact (e.g., bind to) with MUC1 growth factor receptor or its ligands, and methods for treating the same. The invention also relates to assays or use of such compositions for the treatment of patients susceptible to or exhibiting symptoms characteristic of cancer or tumorigenesis. Other compositions of the present invention useful for the treatment or prevention of cancer or tumorigenesis include homologs, analogs, derivatives, enantiomers or functional equivalents. The present compositions can also be packaged in kits in some cases.Type: GrantFiled: September 5, 2002Date of Patent: January 8, 2013Assignee: Minerva Biotechnologies CorporationInventor: Cynthia C. Bamdad
-
Patent number: 8344113Abstract: The invention provides a series of compositions, methods, kits, articles and species associated primarily with the diagnosis and/or treatment of cell proliferation, specifically cancer. Cell proliferation associated with aberrant expression of MUC1 is particularly focused upon. Mechanisms associated with MUC1 cell proliferation are discussed.Type: GrantFiled: January 27, 2010Date of Patent: January 1, 2013Assignee: Minerva Biotechnologies CorporationInventor: Cynthia C. Bamdad
-
Publication number: 20100124789Abstract: Porous members can be positioned so as to partially or fully span channels in microfluidic systems. The porous members can be assembled and/or disassembled in situ. The porous members can be made such that pores are separated by connections including but a single molecule at one location, allowing for a high level of open area in a very small pore size member. The porous member can be made up of colloid particles interconnected with molecular species. These can be used to detect analytes qualitatively and/or quantitatively, or to selectively bind and/or release agents on command for a variety of purposes including first blocking, then opening a channel, concentrating analyte over time followed by release of analyte and detection downstream, etc. Porous members can define valves in multiple-channel systems and, with controlled binding and release of agents at the porous members, these valves can be opened and closed and fluid flow controlled in a multi-channel system.Type: ApplicationFiled: November 5, 2009Publication date: May 20, 2010Applicant: Minerva Biotechnologies CorporationInventor: Cynthia C. BAMDAD
-
Patent number: 7700715Abstract: The invention provides a series of compositions, methods, kits, articles and species associated primarily with the diagnosis and/or treatment of cell proliferation, specifically cancer. Cell proliferation associated with aberrant expression of MUC1 is particularly focused upon. Mechanisms associated with MUC1 cell proliferation are discussed.Type: GrantFiled: November 27, 2001Date of Patent: April 20, 2010Assignee: Minerva Biotechnologies CorporationInventors: Cynthia C. Bamdad, R. Shoshana Bamdad
-
Patent number: 7615340Abstract: Porous members can be positioned so as to partially or fully span channels in microfluidic systems. The porous members can be assembled and/or disassembled in situ. The porous members can be made such that pores are separated by connections including but a single molecule at one location, allowing for a high level of open area in a very small pore size member. The porous member can be made up of colloid particles interconnected with molecular species. These can be used to detect analytes qualitatively and/or quantitatively, or to selectively bind and/or release agents on command for a variety of purposes including first blocking, then opening a channel, concentrating analyte over time followed by release of analyte and detection downstream, etc. Porous members can define valves in multiple-channel systems and, with controlled binding and release of agents at the porous members, these valves can be opened and closed and fluid flow controlled in a multi-channel system.Type: GrantFiled: October 3, 2001Date of Patent: November 10, 2009Assignee: Minerva Biotechnologies CorporationInventor: Cynthia C. Bamdad
-
Publication number: 20060024230Abstract: Customized therapeutics and in situ diagnostics for patient therapy and diagnosis takes advantage of tools including techniques for derivatizing colloids with self-assembled monolayers. This provides the capability of a wide variety of assays including chemical or biochemical agent/agent interaction studies. Bio-derivatized colloids, with or without signaling entities, are used to probe interactions with species on non-colloidal structures. The invention provides techniques for immobilizing colloidal particles on a wide variety of non-colloidal structures. Included is the ability to decorate a variety of non-colloidal structures including beads, with colloids as a detectable assay. This allows, in many cases, assays detectable via the unaided human eye, as well as assays detectable via automated determination of a change of interaction of electromagnetic radiation with the colloids, e.g., absorption, light-scattering, and the like.Type: ApplicationFiled: September 22, 2003Publication date: February 2, 2006Applicant: Minerva Biotechnologies CorporationInventors: Cynthia Bamdad, Shoshana Bamdad Shendelman
-
Publication number: 20050202402Abstract: Chemical, biological, and/or biochemical assays of the invention utilize intermediate binding entities for binding interactions. For example, a colloid particle carrying a species that could harm a component in the assay is allowed to binding interact in the assay only after other, more sensitive components have finished their binding interactions. In another example, multi-step binding interactions are used where single-step interactions could be used, so as to reduce false positives.Type: ApplicationFiled: August 27, 2004Publication date: September 15, 2005Applicant: Minerva Biotechnologies CorporationInventors: Cynthia Bamdad, Shoshana Bamdad Shendelman
-
Publication number: 20050186635Abstract: The invention provides compositions, kits, methods, and species that include electroactive entities which can serve as signaling entities in chemical and/or biochemical assays. The electroactive species can be metallocenes, such as ferrocenes, including substituents that affect the oxidation/reduction potential (redox potential) of the species. By controlling the redox potential of the species, multiple species can be used in a single assay, each species having a different redox potential, for simultaneous signaling of different binding events. Additionally, species having redox potentials lower than 490 mV can be provided, allowing signaling within a potential range easily detectable in the presence of biological fluids.Type: ApplicationFiled: August 6, 2004Publication date: August 25, 2005Applicant: Minerva Biotechnologies CorporationInventors: Cynthia Bamdad, Shoshana Shendelman, Michael Frid
-
Publication number: 20050064446Abstract: The invention provides novel techniques for determining the interaction between binding partners. The first binding partner is immobilized to a surface or a colloid and a second binding partner immobilized to a surface or a colloid. Non-specific binding techniques, including a SAM, provide for the immobilization of a wide variety of species. A mixture may be separated into various components and these components may then be fastened to either the colloids or the surfaces. Binding interaction between the binding partners may be determined through a variety of assays.Type: ApplicationFiled: January 23, 2004Publication date: March 24, 2005Applicant: Minerva Biotechnologies CorporationInventors: Cynthia Bamdad, Shoshana Bamdad Shendelman
-
Publication number: 20050053964Abstract: Methods, assays, and components are described in which biological samples can be rapidly and sensitively analyzed for the presence of species associated with neurodegenerative disease. Techniques and components are provided for diagnosis of disease, as well as for screening of candidate drugs for treatment of neurodegenerative disease. The techniques are simple, extremely sensitive, and utilize readily-available components. Binding species, capable of binding a neurodegenerative disease aggregate-forming or aggregate-forming species, are fastened to surfaces of electrodes and surfaces of particles, or provided free in solution, to bind aggregate-forming species and/or be involved in aggregation.Type: ApplicationFiled: January 13, 2004Publication date: March 10, 2005Applicant: Minerva Biotechnologies CorporationInventors: Cynthia Bamdad, Shoshana Shendelman
-
Publication number: 20050014784Abstract: A treatment for cancer is provided. The treatment may include administering a therapeutic amount of L-histidine, D-cycloserine, quisqualic acid or suramin or analogs thereof.Type: ApplicationFiled: November 14, 2003Publication date: January 20, 2005Applicant: Minerva Biotechnologies CorporationInventors: R. Shendelman, Cynthia Bamdad
-
Patent number: 6723517Abstract: Weak binding motifs were transformed into a high affinity ligand surface by using a heterologous self-assembled monolayer (SAM) as a rigid scaffold to present discrete binding moieties, in a controlled geometry, to a target molecule. At a critical ligand density, the discrete binding moieties simulated a multivalent ligand and promoted high-affinity, cooperative binding of the target molecule. Statistical calculations were applied to SAM components in solution and gold-sulfur packing dimensions to extract the inter-ligand-distance within the SAM. This distance information is valuable to the rational design of multivalent drugs.Type: GrantFiled: June 2, 1999Date of Patent: April 20, 2004Assignee: Minerva Biotechnologies CorporationInventor: Cynthia Carol Bamdad